Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma
Clinical Lung Cancer - United States
doi 10.1016/j.cllc.2019.10.002
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2020
Authors
Publisher
Elsevier BV